Big announcement

1. Shell's adjusted net profit in 2023 was 9.798 billion yuan, an increase of 244.7% year-on-year

$BEKE-W (02423.HK)$According to the announcement, net revenue for 2023 was RMB 77.8 billion, an increase of 28.2% over the previous year. Net profit for 2023 was RMB5.89 billion, while net loss for 2022 was RMB1,397 billion. Adjusted net profit for 2023 was RMB 9.798 billion, up 244.7% year on year.

2. Tourover's adjusted net profit in 2023 was 481 million yuan, turning a year-on-year loss into a profit

$TUHU-W (09690.HK)$Announced 2023 results, revenue of approximately RMB 13.601 billion, up 17.8% year on year; gross profit of approximately RMB 3.359 billion, up 48% year on year; adjusted net profit of approximately RMB 481 million, adjusted net loss of approximately RMB 552 million for the same period in 2022; profit attributable to parent company owners of approximately RMB 6.703 billion, loss due in 2022 of approximately RMB 2,136 billion; and basic profit per share.

3. Weibo's net profit in 2023 was US$342.6 million, up 300.4% year-on-year

$WB-SW (09898.HK)$It was announced that in fiscal year 2023, net revenue was US$1.76 billion, a year-on-year decrease of 4%. Net profit attributable to Weibo shareholders was US$342.6 million, up 300.4% year over year. This is a diluted net income of $1.43 per share. The company's board of directors has approved a special cash dividend of $0.82 per common share and American Depositary Shares.

4. Ping An of China: The total original premium income for the first two months was about 192,819 billion yuan

$PING AN (02318.HK)$An announcement was issued. From January 1, 2024 to February 29, 2024, Ping An Financial Insurance, Ping An Life Insurance, Ping An Pension, and Ping An Health received original premium income of 50,487 billion yuan, 133.844 billion yuan, 4.643 billion yuan, and 38.44 billion yuan respectively, for a total of about 192,819 billion yuan.

5. China Taibao: Pacific Life's original premium income in the first two months was 63.274 billion yuan, a year-on-year decrease of 9.3%

$CPIC (02601.HK)$An announcement was issued. From January 1, 2024 to February 29, 2024, Pacific Life and Pacific Financial Insurance received original premium income of 63.274 billion yuan and 38.977 billion yuan respectively, a year-on-year decrease of 9.3% and an increase of 6.2%, respectively.

6. China Shenhua: Coal sales volume in the first two months was 77.1 million tons, up 12.7% year on year

$CHINA SHENHUA (01088.HK)$An announcement was issued. From January to February 2024, commercial coal production totaled 53.1 million tons, up 0.6% year on year; coal sales volume was 77.1 million tons, up 12.7% year on year. Total electricity generation was 37.25 billion kilowatt-hours, up 12.9% year on year; total electricity sales volume was 35.13 billion kilowatt-hours, up 13% year on year.

Financial data

$BEKE-W (02423.HK)$Adjusted net profit for 2023 was $9.798 billion, up 244.7% year on year

$TUHU-W (09690.HK)$Adjusted net profit of $481 million in 2023, turning a year-on-year loss into a profit

$WB-SW (09898.HK)$2023 net profit of US$342.6 million, up 300.4% year-on-year

$BOC AVIATION (02588.HK)$Record net profit after tax of $764 million for the year, with final interest of $0.2721

$FERRETTI (09638.HK)$Profit attributable to shareholders for the year was about 83 million euros, an increase of about 37.8% over the previous year

$FOSUN TOURISM (01992.HK)$Turned a loss into profit of $307 million in 2023

$UNITED LAB (03933.HK)$Yingxi: Expected annual profit of about 2.6 billion yuan

Operational data

$PING AN (02318.HK)$: The total original premium income for the first two months was about 192,819 billion yuan

$CPIC (02601.HK)$: Pacific Life's original premium income in the first two months was 63.274 billion yuan, down 9.3% year on year

$CHINA SHENHUA (01088.HK)$: Coal sales volume in the first two months was 77.1 million tons, up 12.7% year on year

Pharmaceutical Innovation

$HENLIUS (02696.HK)$: A phase 1 clinical study of injectable HLX42 (targeted EGFR antibody - novel DNA topoisomerase I inhibitor conjugate drug) in patients with advanced/metastatic solid tumors completed the first patient administration in China

$HANSOH PHARMA (03692.HK)$Concluded a licensing agreement with Promise Biotechnology (Zhuhai)

Equity incentives

$SAMSONITE (01910.HK)$: It is recommended to grant rewards in excess of 0.1% of the personal limit in accordance with the share award scheme

Increase or decrease holdings

$DONGFENG GROUP (00489.HK)$Controlling shareholders increased their holdings of the company's H shares by 3.32 million

$HORIZON CD (09930.HK)$Acquired 200,000 shares each by Executive Director and CEO Pan Yang and Executive Director and Co-Chief Financial Officer Tang Li

Repurchase cancellation

$HSBC HOLDINGS (00005.HK)$3.51 million shares were repurchased at HK$209 million on March 13

$AIA (01299.HK)$3.1016 million shares were repurchased at HK$193 million on March 14

$YUM CHINA (09987.HK)$On March 13, 90,000 shares were repurchased at HK$30.79 million

$SWIRE PACIFIC A (00019.HK)$On March 14, 410,000 shares were purchased at HK$27.42 million

$STANCHART (02888.HK)$On March 13, it cost £24.1363 million to buy back 3.65 million shares

$KUAISHOU-W (01024.HK)$On March 14, 392,000 shares were purchased at HK$19.927 million

$XIAOMI-W (01810.HK)$161.5 million shares cancelled on March 14

editor/tolk